Valneva's Chikungunya Vaccine Candidate - VLA 1553
A potential single-shot vaccine against a severe, growing threat
VLA1553 is a monovalent, single dose, live-attenuated vaccine candidate for protection against chikungunya. It was granted Fast Track designation by the US Food and Drug Administration (FDA) in December 2018 (see press release
In January 2019, Valneva reported positive Phase 1 interim results. The results showed an excellent immunogenicity profile after a single-shot vaccination and an acceptable safety profile, supporting further development (see press release
The Phase 1 clinical trial being conducted in the US evaluates the safety and immunogenicity of VLA1553. It is a randomized, observer-blinded, dose-escalation, multi-center study. The trial investigates three different dose levels of VLA1553 in 120 healthy adults vaccinated with a single-shot immunization. Final Phase 1 results are expected mid-2019.
There is currently no antiviral treatment for CHIKV infection and no licensed vaccine to prevent the disease.
The global market for a chikungunya vaccine is estimated at approximately
€500 million annually1
1 Company estimate supported by independent market studies